The specific aims of the Clinical Core are threefold: (1). To prospectively follow five longitudinal cohorts of subjects at risk for neurodegenerative dementia. The central hypothesis of the UTSW ADC is that vascular risk factors in elderly individuals are important contributors to neurodegenerative dementias, and that such patients can be identified by their clinical and psychometric profile, neuroimaging studies, and biochemical markers. Support for this hypothesis will be obtained through prospectively following 5 cohorts: (a). Patients with Mild Cognitive Impairment (MCI). A cohort of 150 subjects with MCI (CDR = 0.5) will be recruited and followed for three years or until they convert to AD. (b). Patients with early Alzheimer's disease (AD). 150 subjects with possible or probable AD in the early stages of their illness (CDR = 1) will be followed for until they progress to CRD = 2. (c). Patients with non-AD dementias. A cohort of 100 patients with non-AD dementia (50 with Fronto-temporal dementia (FTD), and another 50 with dementia and psychotic features (presumed Lewy-body disease (LBD)) will be recruited and followed until death, (d). Controls for cohorts (a) - (c): 150 subjects with no cognitive complaints will be recruited from among spouses, caregivers, and siblings of subjects enrolled in cohorts (a) - (d). (e). Native American cohort. Subjects with dementia (50 subjects) and matched controls recruited at our Satellite clinic in Talahina, OK will be followed prospectively until death. All cohorts will receive uniform evaluations, including MRI scans and biomarker assays for candidate plasma markers and genetic polymorphisms. Substantial efforts will be made to obtain a high autopsy rate among subjects enrolled in the longitudinal cohorts. (2). To support investigator-initiated research on neurodegenerative dementias by researchers at UT Southwestern. A key function of this Core is to provide logistical support and a source of well-studied patients and biological fluids for investigator-initiated projects (funded through RO1, RO3, K23, NACC, Alzheimer's Association, or philanthropic organizations) by UTSW faculty. Several of these are ongoing and discussed in the narrative. All patients enrolled in these studies receive a uniform evaluation, as the Clinical Core Cohorts (in specific aim (1) above). (3). To support multi-institutional observational studies and clinical trials in neurodegenerative dementias. Since much important research on neurodegenerative disorders requires large cohorts that can only be obtained through large collaborative efforts, the third aim of the Clinical Core is to support the participation by the UTSW ADC in multi-center studies. At present these include the NIA Genetics Initiative, FTD-PET study, and multiple clinical trials sponsored by the AD Cooperative Study. All patients enrolled in these studies receive a uniform evaluation, as the Clinical Core Cohorts (in specific aim (1) above).

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG012300-13
Application #
7309779
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2006-04-01
Budget End
2007-03-31
Support Year
13
Fiscal Year
2006
Total Cost
$491,167
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
LoBue, Christian; Woon, Fu L; Rossetti, Heidi C et al. (2018) Traumatic brain injury history and progression from mild cognitive impairment to Alzheimer disease. Neuropsychology 32:401-409
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Rosenberg, Roger N; Fu, Min; Lambracht-Washington, Doris (2018) Active full-length DNA A?42 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology. Alzheimers Res Ther 10:115
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Rosenberg, Roger N; Fu, Min; Lambracht-Washington, Doris (2018) Intradermal active full-length DNA A?42 immunization via electroporation leads to high anti-A? antibody levels in wild-type mice. J Neuroimmunol 322:15-25

Showing the most recent 10 out of 385 publications